The Cross-Border Biotech Blog

MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for April 13th, 2015! The past week saw activity in the M&A and financing spaces. For details the major stories, as well as for the rest of the week’s news, continue reading this week’s Monday Deal Review! Affinium Pharmaceuticals, which has developed innovative anti-infective medicines, has been acquired […]

read more


Q1_2015_Part1_Title

Overall Share Price Performance for the Canadian Healthcare Sector Comparable to U.S. Biotech   In order to assess share price performance among the Canadian public healthcare companies, I select companies at the beginning of each year which are categorized in two ways: share price to start the year and type of company. The share price […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for April 10th, 2015!   J Allergy Clin Immunol. 2015 Apr;135(4):946-955.e9. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.   Nat Nanotechnol. 2015 Mar 30. doi: 10.1038/nnano.2015.25. In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging.   EMBO J. 2015 Mar 27. pii: […]

read more


Part_6_BiotechBlackBox

Theratechnologies Case Study – along the path to regulatory approval of tesamorelin In Part 5 of this blog series, the early corporate history of Theratechnologies was outlined, culminating in the decision to focus on the clinical development of analogs of growth hormone-releasing factor (GRF). GRF is the master hormone which naturally stimulates secretion of growth […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for April 6th, 2015! The past week saw Valeant complete the purchase of Salix Pharmaceuticals, which now becomes a wholly owned subsidiary of Valeant. In related news, Salix announced that they will be redeeming $750 million in senior notes by May 4, 2015. For more on this story, […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for March 30th, 2015!   The past week saw Valeant close their offering of 7,286,432 shares, raising proceeds of about $1.45 billion. For details on this financing, as well as for the rest of the week’s stories, continue reading this week’s Monday Deal Review! Valeant Pharmaceuticals International, Inc (NYSE: […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for March 27th, 2015! Mucosal Immunol. 2015 Mar 18. doi: 10.1038/mi.2015.15. TGF-β-mediated airway tolerance to allergens induced by peptide-based immunomodulatory mucosal vaccination.   Stem Cells. 2015 Mar 12. doi: 10.1002/stem.1994. Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations.   Neuron. 2015 […]

read more


Part5_Biotech_Black_Box

Theratechnologies Case Study – early company history In the Theratechnologies (TSX: TH) case study which I will cover in the next several blogs, I will ask four main questions. In order to get the background to answer the first question, the key source of information is the AIFs found at http://www.sedar.com. The oldest AIF from […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for March 16th, 2015! *A day late, but here is the Monday Deal Review for March 16th. The big news this week was Valeant’s big win over Endo International for acquisition of Salix Pharmaceuticals.   Valeant raised the price for Salix by about a billion US dollars in a new […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for March 9th, 2015!   *A day late, but here is the Monday Deal Review for March 9th. This week, Valeant announced that its Canadian subsidiary VRX Escrow Corp. has launched an offering of the U.S. dollar equivalent of approximately $9.6 billion aggregate principal amount of senior unsecured notes […]

read more